Understanding the chronic disease patient journey in emerging markets
In this paper, we explore the chronic disease patient journey in emerging markets and provide you with the insights you require to identify the key inflection points in these rapidly changing and diverse regions.
With growing urban populations and increasing purchasing power, emerging markets remain an attractive prospect for growth. A high proportion of the urban emerging market population already suffers from chronic diseases and prevalence is set to further increase as lifestyles become closer to those in the West. The chronic disease patient is a critical stakeholder in emerging markets because they often have to pay for their healthcare out of pocket. Moreover, these markets often don’t have formal primary care systems, so the patient is the only constant in the journey. Understanding their journey is critical in order to best leverage these potential new markets.
US Presidential Election: The legacy of the Affordable Care Act and the future for healthcare
Our latest Free Thinking white paper explores the legacy of the Affordable Care Act and the future for healthcare
As US citizens prepare to vote for a new President on Tuesday 8th November, we ask, what is the likely impact of a Republican or Democrat win on the future of the ACA, the health system and the pharma industry?
We spoke to John Leifer, author and strategic consultant to the healthcare industry, to see which way he thinks the wind is blowing.
Are biosimilars the answer to the rising cost of RA treatment?
Our latest Free Thinking white paper explores why the uptake of Biosimilars has been slower than expected and asks what's next for RA?
Monoclonal-antibody (mAb) biologics have significantly improved treatment options and outcomes in rheumatoid arthritis (RA), particularly where patients do not respond to conventional disease-modifying anti-rheumatics.
The burden of disease from RA, including the cost of treatment, additional care and loss of productivity, is considerable. With disease onset peaking at 55 to 64 years, this burden will increase as populations age worldwide, aggravated by rising obesity and other characteristics of unhealthy lifestyles. Therapeutic mAbs, are helping to ease that load. As with most biologics, however, they come at a substantial cost.
In a past Free Thinking paper, we looked at the opportunity and challenges for biosimilar mAbs entering the rheumatoid arthritis market. A few years later and according to our Therapy Watch patient record data, uptake of biosimilars remains relatively muted, with marked inconsistencies across the major European markets. With Enbrel biosimilar Benepali about to launch across EU, we ask what’s next for RA?
Emerging Markets: Your Essential Guide
Request your complimentary copy
Traditional and non-traditional emerging markets are increasingly being recognised by the pharmaceutical industry as offering attractive opportunities for growth. The challenge though is where and how to find insight in these less well-known and rapidly changing regions.
Using our combined knowledge and years of experience of working in these territories our emerging markets experts have produced this essential guide to help address some of the core challenges associated with conducting market research in emerging markets.
From promise to practice: immuno-oncology in action
Our latest Free Thinking white paper series explores what the global outlook is like for new immunotherapy products and asks key opinion leaders and payers how they’re faring both clinically and financially
Immuno-oncology therapies that harness the body's own defences to fight off tumours are widely acknowledged as the new frontier in cancer treatment.
Clinical trials of emerging products, both alone and in combination, have delivered impressive evidence of improvements in durability and endpoints such as progression-free survival, and even overall survival. R&D pipelines are stuffed with immuno-oncology prospects across a wide range of indications.
To date, only a few immuno-oncology products have actually reached the market though. Two of them target the anti-PD1/PD-L1 pathway where much of the interest in immuno-oncology is currently invested.
We spoke to key opinion leaders and payers in the US and EU to find out how the new immunotherapy products are faring clinically and financially.